RecruitingNCT07654179

Metformin as Adjunct Therapy in Depression-obesity Comorbidity: Clinical and Genetic Evaluation

This study evaluates the effectiveness of Metformin for people with depression.

Medication studyPakistan

The study in practice

Understand this study

This study evaluates the effectiveness of Metformin for people with depression.

A point to clarify

This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?

Study clarity

Study start dateStarted: June 17, 2026

Recruitment status: Recruiting
Enrollment listed in the registry: 200
Sponsor: Riphah International University
Sponsor type: University
Study type: Drug
Intervention type: Medication / drug
Study phase: Not clearly listed
Locations: Pakistan
Age range: Not clearly listed
Official registry ID: NCT07654179
Official title: Show the full official title
Efficacy of Metformin With Antidepressant Medication as Adjunct Therapy in Depression-obesity Ccomorbidity and Ssociation With NEGR1/RPL31P12 Variants Based on Genotyping

The HopeStage team will email you.

Recruiting

Rawalpindi

A listed location does not confirm current availability.

FAQ

What is this study about?

This study evaluates the effectiveness of Metformin for people with depression.

Who is behind this study?

The study sponsor is Riphah International University, a university.

Does this study involve medication?

Yes. The study involves medication, including Metformin.

Is this study still recruiting?

The registry lists this study as recruiting.

Explore other studies

Answer a few simple questions to explore HopeStage studies by condition, country, and situation.